PSTV
Plus Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.59
P/S
1.55
EV/EBITDA
-0.01
DCF Value
$0.62
FCF Yield
-258.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.5%
Operating Margin
-293.5%
Net Margin
-429.4%
ROE
774.8%
ROA
-137.1%
ROIC
-317.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.4M | $-5.7M | $-0.04 |
| FY 2025 | $5.2M | $-22.4M | $-0.29 |
| Q3 2025 | $1.4M | $-4.4M | $-1,000.00 |
| Q2 2025 | $1.4M | $5.2M | $-162.50 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.02
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.